Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | EVP, Chief Scientific Ofc, COO | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 145,435 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 18,000 · Balance 163,435 Row 2 · 2026-10-05 · Sale · Disposed 18,000 · Balance 145,435 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2030-04-17 | Direct | 46,398 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 18,000 · Balance 46,398 F2: Stock Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
F2: Stock Option is fully vested and exercisable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Icosavax, Inc.
Report date February 19, 2024 · Filed February 21, 2024
Section 16 reporting ended · disclosed 2024-02-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-19 · Other · Disposed 3,695 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-19 · Disposition to issuer · Disposed 7,392 · Balance 0 F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-19 · Disposition to issuer · Disposed 44,556 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89 | Direct | 0 |
Reported balance
After 2024-02-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-19 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2022 Filed Feb 28, 2022 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-22-013687 · doc4.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,926 Underlying: Common Stock · 10,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,000 | $22.00 | $220,000.00 |
DisclosureSEC source: 0001209191-22-013687 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,944 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 22:17 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 10,000 | $2.42 | $24,200.00 |
DisclosureSEC source: 0001209191-22-013687 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,563 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2021. Read SEC document |
| April 01, 2021 Filed Apr 7, 2021 00:04 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 93,340 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001209191-21-025760 · doc4.xml · derivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,340 Underlying: Common Stock · 93,340 shares Expires 2031-03-31 F1 · derivative.exercise_date: 1/48 of shares subject to the option vest on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-21-013791 · doc4.xml · derivative · entry 4 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,926 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,801 | $26.99 | $48,608.99 |
DisclosureSEC source: 0001209191-21-013791 · doc4.xml · nonDerivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,381 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.745 to $27.305. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,199 | $26.43 | $31,689.57 |
DisclosureSEC source: 0001209191-21-013791 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,182 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.70 to $26.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 21:25 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001209191-21-013791 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001209191-21-004750 · doc4.xml · derivative · entry 3 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,926 Underlying: Common Stock · 3,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $25.50 | $76,500.00 |
DisclosureSEC source: 0001209191-21-004750 · doc4.xml · nonDerivative · entry 2 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,381 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $25.50 to $25.74. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 00:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $2.42 | $7,260.00 |
DisclosureSEC source: 0001209191-21-004750 · doc4.xml · nonDerivative · entry 1 Wassil Jim · CIK 0001813798 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,562 shares acquired under the Employment Stock Purchase Plan on November 17, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.